AU4050797A - Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators - Google Patents

Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Info

Publication number
AU4050797A
AU4050797A AU40507/97A AU4050797A AU4050797A AU 4050797 A AU4050797 A AU 4050797A AU 40507/97 A AU40507/97 A AU 40507/97A AU 4050797 A AU4050797 A AU 4050797A AU 4050797 A AU4050797 A AU 4050797A
Authority
AU
Australia
Prior art keywords
diabetes
prevention
treatment
type
cardiovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40507/97A
Inventor
Johan Auwerx
Michael R Briggs
Ranjan Mukherjee
James R. Paterniti
Bart Stael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Publication of AU4050797A publication Critical patent/AU4050797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
AU40507/97A 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators Abandoned AU4050797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2294996P 1996-08-02 1996-08-02
US60022949 1996-08-02
PCT/US1997/013605 WO1998005331A2 (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Publications (1)

Publication Number Publication Date
AU4050797A true AU4050797A (en) 1998-02-25

Family

ID=21812265

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40507/97A Abandoned AU4050797A (en) 1996-08-02 1997-08-01 Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Country Status (3)

Country Link
EP (1) EP0930882A2 (en)
AU (1) AU4050797A (en)
WO (1) WO1998005331A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
NZ508066A (en) 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
DE19823831A1 (en) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
AU4250200A (en) * 1999-04-19 2000-11-02 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
AU4652600A (en) * 1999-04-23 2000-11-10 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptorgamma using differential gene expression
DK1206457T3 (en) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs
WO2001044512A2 (en) * 1999-12-16 2001-06-21 Curagen Corporation Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression
DK1246638T4 (en) * 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Use of extendins and agonists thereof in the treatment of hypertriglyceridemia
WO2001051454A1 (en) * 2000-01-13 2001-07-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB0002667D0 (en) * 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
WO2001066098A2 (en) * 2000-03-09 2001-09-13 Aventis Pharma Deutschland Gmbh Therapeutic uses of ppar mediators
HUP0301146A3 (en) * 2000-04-28 2004-08-30 Sankyo Co 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
MXPA02012619A (en) * 2000-06-16 2003-04-10 Smithkline Beecham Plc Treatment and prevention of cardiac insulin resistance associated conditions.
IT1317885B1 (en) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti USE OF FIBRATES FOR THE PREPARATION OF A USEFUL DRUG IN THE TREATMENT OF CONGESTIAL HEART INSUFFICIENCY.
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
BR0207285A (en) * 2001-02-15 2004-02-10 Pfizer Producs Inc Ppar agonists
CN1275949C (en) 2001-03-28 2006-09-20 先灵公司 Enantioselective synthesis of azetidinone intermediate compounds
CA2445322C (en) * 2001-04-25 2011-06-14 Takeda Chemical Industries, Ltd. Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
ITRM20020014A1 (en) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti DERIVATIVES OF A-PHENYLTHIOCARBOXYL AND A-PHYLYOXYCARBOXYL ACIDS USEFUL FOR THE TREATMENT OF DISEASES THAT RESPOND TO THE ACTIVATION OF
CA2481371A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US7811593B2 (en) * 2002-03-25 2010-10-12 Jian Luo Pharmaceutical composition with combined active agents and methods for using the same
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
EP1388351A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of fibrate to treat weight gain associated with rosiglitazone treatment
KR100875318B1 (en) 2002-11-26 2008-12-22 화이자 프로덕츠 인크. Phenyl Substituted Piperidine Compounds for Use as PPAR Activators
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
CN101772513B (en) 2007-06-04 2013-11-13 协同医药品公司 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (en) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729209A1 (en) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh USE OF BEZAFIBRATE FOR TREATING DIABETES
JP3852621B2 (en) * 1992-01-21 2006-12-06 あすか製薬株式会社 Vascular endothelial cell function improving agent
NZ274346A (en) * 1993-09-15 1997-06-24 Sankyo Co Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
BR9610624A (en) * 1995-09-18 1999-03-16 Ligand Pharm Inc Treatment of dmndi with rxr agonists
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method

Also Published As

Publication number Publication date
WO1998005331A2 (en) 1998-02-12
EP0930882A2 (en) 1999-07-28
WO1998005331A3 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
AU4050797A (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU6773598A (en) Treatment of gastrointestinal disease with ppar modulators
AU1450900A (en) Methods of treatment of type 2 diabetes
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
NO976063D0 (en) Procedure for the treatment of diabetes
AU2621495A (en) Oil well treatment
AU2263197A (en) Diabetes therapy
AU4241596A (en) Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU4130497A (en) Materials and methods relating to the diagnosis and treatment of diabetes and obesity
PH31323A (en) Alkali-treated bagasse and its preparation and use.
AU4329396A (en) Use of 3,4-diphenylchromans
EP0683676A4 (en) Directed biodistribution of small molecules.
AU9778398A (en) Cellulose treatment and the resulting product
AU1115095A (en) Treatment of cellulose
AU4131296A (en) Treatment of disorders with duloxetine
AU4935596A (en) Transgenic fish in the treatment of diabetes
AU6160594A (en) Diabetes prevention and treatment
AU1251197A (en) Treatment of liquors
AU7644194A (en) Diagnosis of insulin-dependent diabetes
AU7484596A (en) Combination therapy for the treatment of diabetes and obesity
AU2870597A (en) Treatment of liquid
GB9606076D0 (en) Diabetes treatment
AU4107797A (en) Compounds for the treatment and prevention of diabetes